Match the depth to the question.
Not every genome needs the same depth. 10× is a cost-efficient tier for copy-number and cohort genotyping studies; 20× balances cost and content for population programmes; 30× is the standard for rare-disease diagnosis, cancer predisposition and discovery-grade variant detection. Nucleome Informatics runs all three tiers on Illumina NovaSeq with a GATK best-practices and DeepVariant analysis pipeline.
Human Whole Genome Sequencing (short read)
Nucleome Informatics offers human whole genome resequencing on Illumina NovaSeq 6000 and NovaSeq X at three coverage tiers, with analysis matched to each tier's detection limits and to your disease area.
What every project includes
- Raw reads (FASTQ, 2×150 bp) with full QC: yield, Q30, mean depth, coverage uniformity, duplication and insert size
- Alignment (BWA-MEM2) to GRCh38, delivered as BAM or space-saving CRAM
- SNV and indel calls (GATK HaplotypeCaller / DeepVariant), with VQSR filtering where cohort size supports it
- CNV calling from read depth at all tiers; structural variant calling (Manta-class) at 20× and 30×
- Annotation (VEP) with population frequencies from gnomAD and Indian datasets (IndiGenomes), and ACMG/AMP classification for clinical-tier projects
- Cohort analyses: ancestry/PCA, relatedness, homozygosity mapping, and PRS where the cohort is powered for it
- A written report with methods, software versions and detection limits for your tier
- Optional Advanced Analysis Package (30×): repeat-expansion screening, SMN1/SMN2 copy-number calling and mitochondrial variant calling
Disease-area applications
- Rare disease: trio or duo WGS at 30× with de novo detection, homozygosity mapping for consanguineous families, CNV/SV calling, and optional ACMG SF v3.3 secondary findings with consent.
- Cardiovascular: cardiomyopathy and arrhythmia genes (e.g. LMNA, MYH7, TTN), familial hypercholesterolaemia (LDLR, APOB, PCSK9), aortopathy and channelopathy genes.
- Cancer: germline predisposition (BRCA1/2, Lynch syndrome genes, TP53); tumour–normal somatic designs are scoped separately at higher depth.
- Metabolic disorders: inborn errors of metabolism such as PKU (PAH), Wilson disease (ATP7B), lysosomal storage, urea-cycle and fatty-acid oxidation defects.
- Non-communicable diseases: type 2 diabetes and MODY (GCK, HNF1A), obesity, chronic kidney disease, and polygenic risk research in cohorts.
Three tiers, at a glance
Choose the tier from the question you need answered. We run the detection-limit calculation with you before samples are committed.
| Tier | Approx. data per genome | Best for | Not recommended for |
|---|---|---|---|
| 10× | ~30–35 Gb | Genome-wide CNV and aneuploidy profiling, cohort genotyping (with joint calling or imputation), ancestry and population structure | Diagnostic SNV/indel calling; heterozygous variant sensitivity is reduced |
| 20× | ~60–70 Gb | Population and cohort programmes, association studies, larger structural variants | Clinical diagnostic reporting where maximum sensitivity is needed |
| 30× | ~90–100 Gb | Rare-disease diagnosis (trio/duo/singleton), cancer predisposition, discovery-grade SNV, indel, CNV and SV detection | Low-level mosaicism and somatic tumour variants, which need higher depth |
Data volumes are approximate sequencing output for a ~3.1 Gb human genome. Even lower-depth "low-pass" sequencing (well below 1×) is used clinically for aneuploidy and large CNVs; 10× gives much finer CNV resolution plus usable SNV data.
From first principles to expert-level analysis
New here? Start with Foundations. Planning a study or reviewing results? Jump to Practitioner or Expert.
Start here if you are new to this service — six ideas that explain what it is and why it matters.
What is whole genome resequencing?
Sequencing an individual's genome and comparing it with the human reference (GRCh38). Reads are aligned to the reference and the differences — variants — are called.
What does "coverage" mean?
10×, 20× or 30× means each base is read, on average, 10, 20 or 30 times. More depth gives more confident variant calls — at higher cost.
What can 10× WGS do?
Profile copy number across the whole genome and genotype common variants economically in large cohorts. It misses a share of heterozygous variants, so it is not used for diagnosis.
Why is 30× the standard?
At 30× the large majority of the genome is covered well enough for confident SNV and indel calling — the depth used by major rare-disease and population programmes worldwide.
Why genome instead of exome?
One test reads coding and non-coding DNA with even coverage, and detects CNVs and structural variants that exome and gene panels often miss.
What sample do I provide?
EDTA blood, saliva or extracted DNA. Trios need samples from the child and both parents. See the sample table below.
For scientists planning a project or reading a report: how each step works and how it can mislead.
Tier selection
CNV and cohort genotyping at 10×; population content at 20×; variant-level diagnosis at 30×. We agree the tier and its detection limits before sequencing.
Library and sequencing
PCR-free libraries avoid amplification bias in GC-rich regions and reduce duplicates; 2×150 bp sequencing on NovaSeq 6000/X with indexed pooling.
Alignment and variant calling
BWA-MEM2 to GRCh38; SNVs/indels with GATK HaplotypeCaller (joint genotyping for cohorts) or DeepVariant; VQSR or hard filters depending on cohort size.
CNV, SV and repeats
Copy number from read depth; structural variants from split-read and discordant-pair evidence. Repeat-expansion screening (ExpansionHunter-class) is part of the Advanced Analysis Package.
Annotation and classification
VEP annotation with gene, consequence and population frequency (gnomAD, IndiGenomes); ACMG/AMP classification for clinical-tier projects.
Sample and cohort QC
Contamination (VerifyBamID-class), sex check, relatedness and duplicate detection, ancestry inference and batch monitoring — before any variant is interpreted.
For study design: the decisions that determine whether the data answers your question.
Detection limits, stated plainly
10× is not used for SNV-level diagnosis; small-CNV and SV sensitivity rise with depth. Every report states the limits of the tier you ordered.
Trio design for rare disease
Trio WGS at 30× with de novo calling gives the highest diagnostic yield for developmental delay and congenital anomalies; consanguineous pedigrees add homozygosity-guided recessive analysis.
Difficult genes and paralogs
Short reads struggle in segmental duplications and pseudogene-affected loci (SMN1/2, GBA1, CYP21A2, HBA1/2, PMS2) and TTN's triplicated exons. Dedicated callers in our Advanced Analysis Package help (e.g. SMN copy number); long-read follow-up resolves the rest.
Germline vs tumour sequencing
Germline predisposition runs at 30×. Somatic tumour–normal designs need higher tumour depth and purity-aware analysis, scoped as a separate programme.
PRS in Indian cohorts
Polygenic scores need large training cohorts and out-of-sample validation. Indian populations are under-represented in published PRS weights, so we state transferability caveats explicitly.
Data management
A 30× genome is ~90–100 Gb of sequence (roughly 60–100 GB of compressed files). We deliver by secure transfer and support repository submission (IBDC, EGA, dbGaP formats).
- Low-pass WGS
- very shallow sequencing (typically below 1×) used for aneuploidy and large CNVs.
- VQSR
- variant quality score recalibration; GATK's cohort-scale filtering method.
- De novo variant
- present in the child but absent from both parents; a key rare-disease signal.
- Homozygosity mapping
- finding long homozygous regions to prioritise recessive variants in consanguineous families.
- PRS
- polygenic risk score; a weighted sum of many risk alleles.
- ACMG SF
- ACMG secondary findings gene list (v3.3, 2025; 84 genes).
WGS, exome or microarray — what each detects
In a meta-analysis of 37 studies and over 20,000 children with suspected genetic disease, diagnostic yield was 41% for WGS, 36% for exome and 10% for chromosomal microarray (Clark et al., 2018).
| Capability | 30× WGS | Exome (WES) | Chromosomal microarray |
|---|---|---|---|
| Coding SNVs and indels | Yes, with even coverage | Yes; coverage varies by capture | No |
| Non-coding, deep-intronic, regulatory | Yes | Largely no | No |
| CNVs | Genome-wide, including small CNVs | Limited, exon-level | Yes, larger CNVs |
| Structural variants and breakpoints | Yes (balanced rearrangements partly) | No | Unbalanced only |
| Repeat expansions | Screening for many known loci (Advanced package) | No | No |
| Mitochondrial genome | Yes (Advanced package) | Limited | No |
Prefer an exome? See Whole Exome Sequencing and Clinical Exome Sequencing, or ask us to compare designs for your cohort.
From sample to report
Every step is versioned and logged, so your analysis can be reproduced and defended.
What to send, what you receive
Typical requirements for PCR-free libraries. Lower-input or difficult samples can often be processed with a PCR-based library — ask us first.
| Sample type | Recommended amount | Quality / handling |
|---|---|---|
| Genomic DNA | ≥1 µg at ≥20 ng/µL | A260/280 1.8–2.0, A260/230 ≥1.8; intact high-molecular-weight DNA, no visible degradation |
| Whole blood | 2–4 mL in EDTA tubes | Ship at 2–8 °C within 3 days, or frozen |
| Saliva | One collection kit per sample | Stabilised saliva kit; ship at room temperature |
| Fresh-frozen tissue | ≥25 mg | Ship on dry ice; FFPE is discussed case by case |
Deliverables
- FASTQ files and a sequencing QC report (yield, Q30, depth, % genome ≥10×/≥20×, duplication, insert size)
- BAM or CRAM alignments to GRCh38
- VCFs for SNVs/indels, CNVs and SVs (tier-dependent), plus annotated variant tables
- For clinical-tier projects: prioritised, ACMG/AMP-classified variants for review by the requesting clinician
- Analysis report with methods, software versions and tier detection limits
Samples are tracked from receipt; data is handled confidentially and delivered by secure transfer. Clinical samples need a signed requisition and consent, including the choice on secondary findings.
Built for the questions you are asking
The platforms, pipelines and standards behind this service.
Illumina NovaSeq 6000 / X
Production-scale 2×150 bp sequencing — the throughput backbone for single genomes and cohort-scale WGS.
Three-tier coverage design
10×, 20× and 30× — depth matched to the question, with detection limits documented for each tier.
GATK best practices + DeepVariant
BWA-MEM2 alignment, joint genotyping for cohorts, deep-learning variant calling, and versioned, reproducible workflows.
Beyond SNVs
CNVs at every tier and SVs at 20× and 30×. Our Advanced Analysis Package adds repeat-expansion screening, SMN1/2 copy number and mitochondrial variant calling.
Consanguinity-aware analysis
Homozygosity mapping, trio de novo detection and recessive prioritisation, with Indian population frequencies in every filter.
ACMG SF v3.3 secondary findings
Optional reporting of actionable findings from the 84-gene ACMG SF v3.3 list, with explicit consent and kept separate from primary results.
Depth and detection in pictures
How coverage tier relates to what can be detected. Both figures are illustrative, not client results or benchmark measurements.
What this service does and does not cover
Service highlights
What you can expect from our team in Hyderabad.
Three tiers, one pipeline family
10×, 20× and 30× on NovaSeq 6000/X with consistent, versioned analysis workflows.
Disease-area expertise
Rare disease, cardiovascular, cancer predisposition, metabolic and NCD cohort programmes.
Built for Indian genomes
Homozygosity-aware analysis and Indian population frequencies for consanguineous and endogamous families.
Honest detection limits
Tier and gene limitations stated in every report, with long-read follow-up available in-house.
Cohort-scale throughput
NovaSeq X capacity for population programmes, with ancestry, relatedness and PRS analyses.
Clinical-grade options
ACMG/AMP classification and ACMG SF v3.3 secondary findings for clinical-tier projects.
Frequently asked, in plain language
From the basics to the finer points of design and interpretation.
basicWhich coverage tier do I need?
basicWhat sample do you need?
basicWhat do I get?
basicHow much data does one genome produce?
intermediateIs 10× WGS useful for diagnosis?
intermediateCan you analyse consanguineous families?
intermediateAre secondary findings reported?
advancedWhat are the short-read blind spots?
advancedCan short-read WGS detect repeat expansions, SMA and mitochondrial variants?
advancedCan you build polygenic risk scores from my cohort?
advancedCan tumour–normal somatic designs be added?
advancedHow is cohort quality controlled?
Key literature & resources
Selected sources behind the methods and figures on this page.
- Lee K, et al. ACMG SF v3.3 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the ACMG. Genetics in Medicine. 2025;27(8):101454.
- Richards S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the ACMG and AMP. Genetics in Medicine. 2015;17(5):405–424.
- DePristo MA, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature Genetics. 2011;43(5):491–498.
- Poplin R, et al. A universal SNP and small-indel variant caller using deep neural networks (DeepVariant). Nature Biotechnology. 2018;36(10):983–987.
- Vasimuddin M, et al. Efficient architecture-aware acceleration of BWA-MEM for multicore systems (BWA-MEM2). IEEE IPDPS. 2019:314–324.
- Chen X, et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics. 2016;32(8):1220–1222.
- Dolzhenko E, et al. ExpansionHunter: a sequence-graph-based tool to analyze variation in short tandem repeat regions. Bioinformatics. 2019;35(22):4754–4756.
- Clark MM, et al. Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases. npj Genomic Medicine. 2018;3:16.
- Karczewski KJ, et al. The mutational constraint spectrum quantified from variation in 141,456 humans (gnomAD). Nature. 2020;581(7809):434–443.
- Jain A, et al. IndiGenomes: a comprehensive resource of genetic variants from over 1000 Indian genomes. Nucleic Acids Research. 2021;49(D1):D1225–D1232.
- Martin AR, et al. Human demographic history impacts genetic risk prediction across diverse populations. American Journal of Human Genetics. 2017;100(4):635–649.
- Qian Y, et al. Validation and depth evaluation of low-pass genome sequencing in prenatal diagnosis using 387 amniotic fluid samples. Journal of Medical Genetics. 2023;60(10):933–938.
- Kariyaiah S, et al. Low pass whole genome sequencing — a cost-effective technique for the identification of aneuploidies and copy number variations: a study of 1372 clinical samples in an Indian cohort. medRxiv. 2025. doi:10.1101/2025.05.18.25327314









